5MRD

Stocks Paring Losses Even as Rate Cut Hopes Dwindle

Despite this week's choppiness, all three major indexes could still nab weekly wins

Digital Content Manager
Nov 14, 2025 at 12:11 PM
facebook X logo linkedin


The Nasdaq Composite (IXIC) is clawing its way out of red territory this afternoon, as Big Tech attempts to rebound. The S&P 500 Index (SPX) has also pivoted higher despite rampant rate cut concerns, with investors now only pricing in a 51% chance of a quarter-point interest rate cut in December, per CME's FedWatch Tool. The Dow Jones Industrial Average (DJI) is sitting out the late-week rally, extending yesterday's steep losses. Despite the general angst on Wall Street lately, all three major indexes have a chance to eke out weekly wins.

Continue reading for more on today's market, including: 

  • C-suite shakeup dings Walmart stock.
  • Chip stock brushes off upbeat quarter.
  • Plus, options traders target AIG; DASH bounces back; and pharma stock halts late-stage trial.
MMC Stats 1114
 
American International Group Inc (NYSE:AIG) stock is down 0.9% to trade at $77.58 at last check, after the insurance company noted in a SEC filing that it will work on its future organizational structure. AIG is seeing unusual options activity today, with 4,230 calls and 4,036 puts traded so far -- volume that is nine times the amount typically seen at this point. Most active is the June 80 call, where new positions are being bought to open. AIG sports a 6.7% year-to-date lead
 
DoorDash Inc (NASDAQ:DASH) stock is leading the SPX today, last seen up 5.7% to trade at $206.31. The security is looking to snap a four-day losing streak with its biggest single-day percentage gain since April, following a dramatic pullback from its Oct. 16, all-time high of $285.35. The $200 region seems to have emerged as a floor. The food delivery stock is now up 22.8% for 2025.
 
Bristol-Myers Squibb Co (NYSE:BMY) stock is pacing the SPX's laggards today, down 3.6% to trade at $46.86. Today's bear gap comes after the drugmaker stopped a late-stage trial with Johnson & Johnson (JNJ) of an experimental blood thinner for survivors of heart attacks, noting an independent review found it was unlikely to meet its primary goal. BMY has shed 19.5% in the last 12 months, and is pulling back from a rally to its highest level since June.

 

BMYd113307293i

 

$40 = 4 Trades That Can Move the Needle

Start your trading week with a ready-to-execute trade hand selected by Schaeffer's very own Senior VP of Research Todd Salamone. 

Our Trade of the Week is backed by 30+ years of experience and will provide you the market insight, research, and trade management you need to act with confidence.

One month. 4 trades. Only $10 per trade!

👉 Click Here to Get Your First Trade Before Monday’s Opening Bell

tesla
 
 
 
 

Follow us on X, Follow us on Twitter